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ABSTRACT 
Background 
Somatic mutations in the epidermal growth factor receptor (EGFR) intracellular 
signalling pathways predict nonFresponse to cetuximab in the treatment of advanced 
colorectal cancer (aCRC). We hypothesized that common germline variants within 
these pathways may also play similar roles. 
 
Methods 
We analysed 54 potentially functional, common, inherited EGFR pathway variants in 
815 aCRC patients treated with oxaliplatinFfluoropyrimidine chemotherapy 
+cetuximab. Primary endpoints were response and skin rash (SR). We had >85% 
power to detect ORs=1.6 for variants with minor allele frequencies >20%. 
 
Results 
We identified five potential biomarkers for response and four for SR, although none 
remained significant after correction for multiple testing. Our initial data supported a 
role for Ser313Pro in  in modulating response to cetuximab F in patients with 
 wild type CRCs, 36.4% of patients with one allele encoding proline 
responded, as compared to 71.2% of patients homozygous for alleles encoding 
serine (OR 0.23, 95% CI 0.09F0.56, =0.0014) and this association was predictive 
for cetuximab (	
	
=0.017); however, independent replication failed to validate 
this association. No previously proposed predictive biomarkers were validated. 
 
Conclusions 
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Our study highlights the need to validate potential pharmacogenetic biomarkers. We 
did not find strong evidence for common germline biomarkers of cetuximab response 
and toxicity. 
 
Key Words: Pharmacogenetics, colorectal cancer, cetuximab, biomarkers.
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INTRODUCTION 
The treatment of colorectal cancer (CRC) is improving with average survival for 
advanced CRC (aCRC) increasing from ~6 months with best supportive care alone, 
through 10F12 months with fluoropyrimidineFbased regimens [1] and up to 16F21 
months with oxaliplatin or irinotecan and a fluoropyrimidine.[2, 3] In addition, 
monoclonal antibodies (McAbs) against the epidermal growth factor receptor (EGFR) 
improve overall survival (OS) in patients with aCRC in whom other treatments have 
failed [4] and,in combination with first line therapy, in those with  wild type 
tumours.[5] EGFR acts as a gateFway for the RasFRafFMAP and PI3KFPTENFAkt 
intracellular signalling pathways. The efficacy of cetuximab and panitumumab (antiF
EGFR McAbs) is dependent upon an absence of somatic mutations in members of 
this signalling cascade such as  [6] and ,[5] and these predictive 
biomarkers help guide the treatment of aCRC.[7] 
 
Inherited factors are also likely to affect response to, and side effects from, 
chemotherapy and biological therapy. Pro241 in ,[8] 61A>G in ,[8, 9] 
His131Arg in ,[10] Val158Phe in ,[10, 11] 765G>C and +8473T>C 
in ,[12] and, Arg521Lys [13] and a (CA)n repeat [11, 14] in  have all 
been suggested to predict response to cetuximab. 
 
The United Kingdom MRC COIN trial (NCT00182715), which consists of 2445 aCRC 
patients treated with oxaliplatinFfluoropyrimidine chemotherapy ±cetuximab, serves 
as an important resource for the discovery of new, and validation of existing, genetic 
biomarkers.[15, 16] We used this resource, together with patients from the allied 
COINFB trial of oxaliplatinFfluoropyrimidine chemotherapy +cetuximab 
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(NCT00640081) [17] to investigate the role of 54 potentially functional, common, 
inherited EGFRFrelated variants in predicting response to, and side effects from, 
cetuximab. 
 
METHODS 
Patients and treatments 
All patients had metastatic or locally advanced colorectal adenocarcinoma and 
received no previous chemotherapy for advanced disease. All patients gave fully 
informed consent for this study (approved by REC [04/MRE06/60]). COIN patients 
were randomised 1:1:1 to receive continuous oxaliplatin and fluoropyrimidine 
chemotherapy (Arm A), continuous chemotherapy +cetuximab (Arm B), or 
intermittent chemotherapy (Arm C).[15, 16] COINFB patients were randomised 1:1 to 
receive intermittent chemotherapy and cetuximab (Arm D) or intermittent 
chemotherapy and continuous cetuximab (Arm E) (Supplementary Figure).[17] 
 
Selection and genotyping of potential pharmacogenetic variants 
Potentially functional inherited variants were sought in 146 genes identified from 
literature reviews as likely to play a role in the EGFR signalling pathways. Variants 
were considered potentially functional if there was previous clinical or biological 
evidence for an effect on response or side effects, if they were nonsynonymous, or if 
they occurred in the promoter region. Variants were mined from dbSNP (v.129, 
http://www.ncbi.nlm.nih.gov/SNP/) and from exome reFsequencing germline data, 
and those with a minor allele frequency (MAF) >5% (Caucasian population) were 
considered for genotyping. Genotyping was carried outusing a custom Illumina 
GoldenGate assay or by inFhouse assays (Supplementary Information). 
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Independent analysis of Ser313Pro in  
We obtained germline DNA samples together with response data for 309 unrelated 
patients with  wildFtype CRCs that were treated with cetuximab alone or in 
combi ation with chemotherapy. These were previously collected as part of an 
international consortium study.[18] We carried out PCR amplification using the 
primers 5’FGGGCCGTAAATACTGATCCCTF3’ and 5’F
TCCAACATTGGGACTGCCGAF3’ and directly sequenced the purified products.In 
total, 81.9% (n=253) of samples were successfully amplified and genotyped. 
 
Clinical parameters assessed 
The primary endpoints were: (i) 12Fweek response, defined as complete response or 
partial response  stable disease or progressive disease at 12Fweeks; and, (ii) 
grade ≥2 skin rash (SR) or cetuximab dose reduction or delay due to SR  
grade <2 SR with no cetuximab dose modification. Response was assessed using 
RECIST criteria and SR toxicity was graded using NCI Common Terminology 
Criteria version 3.0.[19] Secondary efficacy endpoints were OS and overall response 
rate (ORR), and secondary toxicity endpoints were grade ≥2 at any point  
grade <2 for lethargy, nausea or vomiting, diarrhoea, stomatitis, HandFFoot 
Syndrome (HFS), hypomagnesaemia and nail changes.  
 
Sample size and power considerations 
Patients from COIN Arm B and COINFB (those treated with cetuximab) had similar 
efficacy and toxicity outcomes at 12Fweeks, so were combined to increase power, as 
were patients from COIN Arms A and C (no cetuximab). A total of 2183 patients 
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were genotyped, of which 815 received cetuximab (676 had a response outcome 
and 730 had a SR outcome) and 1368 did not receive cetuximab (1169 had a 
response outcome). Based on 676 patients (received cetuximab, genotyped and with 
data on response), we had >85% power (<0.05) to detect an OR of 1.6, equating to 
a 12% difference in response or SR (45% responded or had SR) for a variant with a 
MAF>20%, and an OR of 2.3, corresponding to a 20% difference in response or SR, 
for a variant with a MAF>5%. 
 
Statistical analyses 
Genotypes were tested for deviation from the Hardy Weinberg Equilibrium (HWE) 
using a chiFsquared test with <9.3x10F4 (multiple testing for n=54 variants). 
Pharmacogenetic analyses were carried out using Stata 12.1 with a coFdominant 
model, and tested using the likelihoodFratio chiFsquared statistic. For significant 
associations (<0.05), subsequent analyses were carried out using logistic 
regression under the bestFfitting allele model and adjusted for the type of 
fluoropyrimidine. Correction for multiple testing was by Bonferroni. 
 
RESULTS 
We extracted DNA from peripheral blood samples from 2183 unrelated patients with 
aCRC from the UK national trials COIN (2070 of the 2445 randomised) and COINFB 
(113 of the 226 randomised). All patients received oxaliplatin and fluoropyrimidine 
chemotherapy ±cetuximab as continuous or intermittent regimens. For the first 12F
weeks, at which point the primary pharmacogenetic analyses were carried out, 
treatments were identical in all patients apart from the choice of fluoropyrimidine 
(n=834, 38% received OxMdG and n=1349, 62% received Xelox) together with the 
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randomisation of ±cetuximab (n=815, 37% received cetuximab) (Supplementary 
Figure, Supplementary Table S1). Here, we focussed on the analysis of the 815 
patients treated with cetuximab, to identify predictive biomarkers for this biological 
therapy (Figure). 
 
Eighty potentially functional, common (MAFs >5%), inherited, coding and promoterF
region variants were identified in the EGFR pathway. Of these, 71 passed 	
		 
locus conversion on the GoldenGate platform and 51 were successfully assayed. 
Four variants were assayed ‘in house’ of which three were successfully genotyped. 
No genotypes deviated from the HWE. Therefore, in total, 54 variants were 
considered for the analyses of response to, and side effects from, cetuximab 
(Supplementary Table S2, Figure). 
 
Primary analyses for response 
Five variants were associated with response (<0.05), the most significant being a 
nonsynonymous variant (Ser313Pro) in the phosphatidylinositol 3Fkinase regulatory 
(PIK3R) subunit 2 (Table, Supplementary Table S3); 40.3% of patients with an allele 
encoding proline responded as compared to 60.4% of patients homozygous for 
alleles encoding serine (OR=0.44, 95% CI 0.26F0.75, =0.002). We stratified by 
 status and found that this association was only significant in patients with 
 wild type CRCs (36.4% of patients with an allele encoding proline responded 
as compared to 71.2% of patients homozygous for alleles encoding serine, OR 0.23, 
95% CI 0.09F0.56, =0.0014; [as compared to 40.0% and 50.5% of patients with 
 mutant CRCs respectively, OR 0.65 95% CI 0.30F1.43, =0.29; 
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	
	
=0.076], Supplementary Table S4). No associations remained significant 
after correction for multiple testing. 
 
We analysed Ser313Pro in in  wildFtype patients who did not receive 
cetuximab (from Arms A and C of COIN), and observed a predictive effect for 
response to cetuximab (	
	
=0.017, Supplementary Table S4). 
 
We sought independent evidence for a predictive role of Ser313Pro by analysing 
germline DNA samples from 309 unrelated patients with  wildFtype CRCs that 
were treated with cetuximab. We had >90% power to observe an OR 0.23 equating 
to a 35% difference in response (found in COIN). We did not find any effect on 
objective response, with an allelic trend in the opposite direction: 45.8% (11/24) of 
patients with one allele encoding proline had a response, as compared to 32.2% 
(68/211) of patients homozygous for alleles encoding serine (=0.18). 
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Table . Variants with <0.05 for the primary endpoints 

Endpoint rs no. Gene Variant 
Endpoint 
+/. 
AA AB BB 
Χ
2
 (df) 
.value
a
 
OR (95% CI) 
.value
b
 
Predictive for cetuximab (YES/NO) 
OR (95% CI) & .value for no cetuximab
c
 
 interaction
Any  status  wild type 
12.week 
response 
rs1011320  Ser313Pro 
+ 0 25 371 9.42 (1) 
0.002 
0.44 (0.26, 0.75) 
0.002 (d) 
NO 
0.73 (0.50,1.07), 0.11 
	
	
 = 0.13 
YES 
0.82 (0.47, 1.45), 0.51 
 	
	
 = 0.017
F 0 37 243 
rs17537869  Arg268Trp 
+ 1 61 336 8.13 (2) 
0.017 
1.66 (1.03, 2.67) 
0.037 (d) 
YES 
0.64 (0.45, 0.89), 0.009 
	
	
 = 0.001 
NO 
0.68 (0.41, 1.11), 0.12 
 	
	
 = 0.052
F 3 25 253 
rs4444903 
c.1F382 
A>G 
+ 135 218 45 7.54 (2) 
0.023 
0.56 (0.36, 0.86) 
0.008 (r) 
NO 
0.91 (0.67, 1.25), 0.56 
	
	
 = 0.070 
NO 
0.73 (0.47, 1.14), 0.17 
 	
	
 = 0.17
F 94 135 52 
rs78803121  Cys141Phe 
+ 1 34 363 7.44 (2) 
0.024 
0.57 (0.37, 0.89) 
0.013 (a) 
NO 
0.85 (0.60,1.21), 0.38 
	
	
 = 0.16 
NO 
0.83 (0.50, 1.39), 0.49 
 	
	
 = 0.15
F 5 35 251 
rs5275 
c.1812+430 
T>C 
+ 142 196 60 6.95 (2) 
0.031 
1.51 (1.10, 2.06) 
0.010 (d) 
YES 
1.02 (0.80, 1.28), 0.90 
	
	
 = 0.046 
NO 
1.09 (0.78, 1.53), 0.60 
	
	
 = 0.21
F 128 114 39 
  	         
SR 
rs785467  Asn283Lys 
+ 160 182 34 9.55 (2) 
0.009 
1.56 (1.17, 2.10) 
0.003 (d) 
YES 
0.43 (0.16, 1.17), 0.099 
	
	
 = 0.014 
n/a 
F 190 133 31 
rs16858808  Arg335Cys 
+ 0 23 353 5.29 (1) 
0.022 
2.36 (1.10, 5.04) 
0.027 (d) 
NO 
1.85 (0.42, 8.24), 0.42 
	
	
 = 0.81 
n/a 
F 0 10 343 
rs41292521   Ser438Leu 
+ 0 25 351 5.17 (1) 
0.023 
2.26 (1.09, 4.68) 
0.028 (d) 
NO 
1.24 (0.16, 9.47), 0.84 
	
	
 = 0.58 
n/a 
F 0 11 342 
rs602990 !! Met584Val 
+ 83 163 130 6.85 (2) 
0.033 
n/a (od) 
NO 
χ2 (df) = 0.33 (2), 0.85  
 	
	
 = 0.91 
n/a 
F 61 187 106 
 
Results shown using a coFdominant modela and, odds ratios and 95% confidence intervals using the best model that fitted the datab [models for (d) = dominant allele, (r) = recessive 
allele, (a) = additive allele, (od) = overFdominant allele]. cPatients not treated with cetuximab were from Arms A and C of COIN. For endpoints, + = patients that responded or had SR, F 
= patients that did not respond or have SR. A and B alleles were assigned by Illumina; the common allele encodes the wild type amino acid, so for Ser313Pro the B allele encodes Ser 
and for Asn283Lys the A allele encodes Asn. n/a, not applicable for overFdominant model and SR is unlikely to be related to the tumours molecular profile. No associations were 
significant after correction for multiple testing. 
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Arg268Trp in  was also associated with response in COIN/COINFB (OR=1.66, 
95% CI 1.03F2.67, =0.037) and was predictive for cetuximab (	
	
=0.001, 
Table); however, this effect was only significant in the  mutant subset 
(	
	
=0.034, Supplementary Table S5) and was not significant after correction 
for multiple testing. 
 
Primary analyses for SR 
Four variants were associated with SR (<0.05), the most significant being 
Asn283Lys in (Table, Supplementary Table S3); 56.8% of patients with at 
least one allele encoding lysine had severe SR as compared to 45.7% of patients 
homozygous for alleles encoding asparagine (OR 1.56, 95% CI 1.17F2.10, =0.003). 
This association was predictive for cetuximab (	
	
=0.014, Table); however, no 
associations remained significant after correction for multiple testing.There was no 
interaction with the type of fluoropyrimidine used (=0.66). 
 
Previously proposed predictive biomarkers 
Numerous germline variants in the EGFR pathway have been suggested to be 
predictive biomarkers for cetuximab response.[8F14] These were tested as part of 
our study and only c.1F382A>G (61A>G) in  and c.1812+430T>C in  
were significantly associated with response (=0.008 and 0.010, respectively), and 
trended towards (	
	
=0.07), or had a significant (	
	
"0.046), predictive 
effect for cetuximab (irrespective of  status), respectively (Table). However, 
neither were predictive in the  wild type subset (	
	
 = 0.17 and 0.21, 
respectively; Table). 
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Secondary analyses 
Ser313Pro in  was associated with OS and ORR, Cys141Phe in  with 
ORR and Asp784Val in  with OS (Supplementary Table S6). Val906Ile in 
# was associated with lethargy, His321Arg in  and Arg574Pro in 
##$ with nausea/vomiting, Lys344Thr in % and Val906Ile in # with 
diarrhoea, Arg298His in , Met322Thr in , Phe212Val in  and 
c.1F1671insA in ## with stomatitis, c.1F382 A>G in , Pro1170Ala in &&, 
Cys141Phe in  and Asp806Asn in # with HFS, Tyr187His in ' 
with hypomagnesaemia and Arg335Cys in , Glu920Val in  and Lys220Arg 
in ' with nail changes (Supplementary Table S7). None of the associations 
remained significant after correction for multiple testing. 
 
DISCUSSION 
In total, we analysed 54 inherited variants from genes in the EGFRFrelated pathways 
for a potential role in response to, or side effects from, cetuximab in the treatment of 
aCRC. Given the size of our cohort, we had considerable power to detect common 
alleles of small effects. Although, we identified five potential biomarkers for response 
and four for SR in our primary analyses, none remained significantafter adjusting for 
multiple testing. Numerous common inherited biomarkers for cetuximab response 
have been proposed by others;[8F14] however, many of these have been derived 
from studies using small cohorts of patients and, consequently, the majority have 
failed,[14] or have been inconsistent upon independent replication.[12, 14, 18, 20] In 
our study, we analysed these variants and had limited evidence for c.1F382A>G 
(61A>G) in  and c.1812+430T>C (+8473T>C) in  in predicting response 
to cetuximab. However, neither effect was found in the important  wildFtype 
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subset (which had the potential to respond), and, our data did not support the 
proposed direction of allelic effect for c.1F382A>G.[12, 14] Therefore, we have no 
strong evidence for a predictive role for any of these variants. 
 
Our study clearly highlights the need to validate potential pharmacogenetic 
biomarkers. Initial data from our study strongly supported a role for Ser313Pro in 
 in modulating response to cetuximab and this association was only 
significant in those patients with CRCs that were wild type for , so had the 
potential to respond, and was not found in patients that did not receive cetuximab, 
regardless of their  status, so was unlikely to be a prognostic effect. However, 
we carried out a wellFpowered independent analysis of unrelated patients and failed 
to validate our initial observations, suggesting that this was a chance event. 
 
In conclusion, we have carried out a comprehensive, wellFdesigned study to identify 
common germline biomarkers for cetuximabFrelated outcomes, but failed to establish 
strong evidence for their existence.  
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LEGEND TO FIGURE 
Figure. CONSORT diagram of the study design and analyses. Shown are the 
numbers of variants analysed, together with the numbers of patients studied, and the 
primary and secondary endpoints. MAF, minor allele frequency; pts, patients; SR, 
skin rash; OS, overall survival; ORR, overall response rate. 
Page 21 of 37
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only



	

	




	



	
		
	


	 !	

"#
	#$	
#
	
#


!	
%&'()*+,-++(-++./01


Page 22 of 37
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
1 
 
Supplementary Information for “Comprehensive Pharmacogenetic Profiling of the 
Epidermal Growth Factor Receptor Pathway for Biomarkers of Response to, and 
Toxicity from, Cetuximab” 
 
Supplementary Methods 
Genotyping 
Most variants were single nucleotide polymorphisms (SNPs) genotyped using a 
custom Illumina GoldenGate assay. The Assay Design Tool (Illumina) was used to 
anticipate genotyping success. This was based on the designability rank and 
validation class for a given SNP. When two or more SNPs occurred within 60bp of 
one another, the SNP selected for submission was chosen based on its designability 
score, MAF and likelihood of being functional using in silico analyses (PolyPhen or 
align-GVGD). For the 51 SNPs successfully genotyped on the GoldenGate platform, 
the mean GC score was 0.83 (range 0.49-0.96), genotype success rate was 99.9% 
(41522/41565) and there was 100% concordance between duplicate samples. 
 
Four variants were assayed ‘in house’ because they were not suitable for (n=3), or 
failed (n=1), GoldenGate genotyping. The (CA)n repeat in intron 1 of EGFR 
(rs11568315) was assayed using the primers 5’-GGCTCACAGCAAACTTCTCC-3’ 
and 5’-TATGGTCGGTAGTCACGAAGC-3’ and the c.1-1671 insertion A in the MMP3 
promoter (rs35068180) was assayed using the primers 5’-
AGCTGCCACAGCTTCTACAC-3’ and 5’-GTATTCTATGGTTCTCCATTC-3’. One of 
the primers for each pair was fluorescently labelled and PCR products were 
analysed on an ABI3100 using the GeneScan Analysis Software (ABI). Phe212Val in 
FCGR3A (rs396991) was assayed using a Taqman real time quantitative PCR assay 
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(ABI). The -216 G>T variant in the EGFR promoter (rs17288945) was analysed 
using a Taqman assay, allele-specific amplification and by direct sequencing without 
success. 
 
 
Supplementary Figure: Treatment schedules for patients in COIN and COIN-B. 
 
 
Patients received continuous oxaliplatin and fluoropyrimidine chemotherapy (Arm A), 
continuous chemotherapy +cetuximab (Arm B), intermittent chemotherapy (Arm C), 
intermittent chemotherapy with cetuximab (Arm D) and intermittent chemotherapy 
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with continuous cetuximab (Arm E). In all patients, treatment was identical for the 
first 12-weeks apart from the choice of fluoropyrimidine together with the 
randomisation of ±cetuximab. Primary pharmacogenetic analyses were carried out at 
12-weeks. For arms with intermittent therapy, treatment was stopped from 12-weeks 
(apart from cetuximab in Arm E) if there was complete response, partial response or 
stable disease and re-initiated upon disease progression.
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Supplementary Tables: 
 
Supplementary Table S1 - Clinicopathological data for patients in COIN and COIN-B, 
and heterogeneity across analysis groups and their arms (genotyped patients) 
 
  + cetuximab - cetuximab P1 P P 
  
COIN 
Arm B 
COIN-B 
Arms D+E 
COIN 
Arms A+C 
 D vs E A vs C 
n =  702 113 1368    
  
      
Age at 
randomisation 
Mean (S.D.) 62.9 (9.8) 61.9 (10.5) 62.4 (9.8) 0.39 0.82 0.20 
<20 0 (0.0) 0 (0.0) 1 (0.1) 0.69 0.32 0.30 
20-49 74 (10.5) 12 (10.6) 133 (9.7)    
50-59 147 (20.9) 25 (22.1) 329 (24.1)    
60-69 289 (42.2) 50 (44.3) 563 (41.2)    
70-79 186 (26.5) 24 (21.4) 335 (24.5)    
80-89 6 (0.9) 2 (1.8) 7 (0.5)    
  
      
Sex Female 231 (32.9) 48 (42.5) 465 (34.0) 0.14 0.77 0.92 Male 471 (67.1) 65 (57.5) 903 (66.0)    
  
      
WHO-PS 
0 330 (47.0) 58 (51.3) 639 (46.7) 0.76 0.89 0.99 
1 325 (46.3) 46 (40.7) 623 (45.5)    
2 47 (6.7) 9 (8.0) 106 (7.8)    
  
 
 
    
Primary Site 
Colon 377 (53.7) 69 (61.1) 739 (54.0) 0.85 0.0092 0.21 
Rectum 229 (32.6) 32 (28.3) 424 (31.0)    
RSJ 95 (13.5) 12 (10.6) 202 (14.8)    
Other 1 (0.1) 0 (0.0) 2 (0.2)    
Missing 0 (0.0) 0 (0.0) 1 (0.1)    
  
 
 
    
Number of 
metastatic 
sites 
0 5 (0.7) 1 (0.9) 9 (0.7) 0.37 0.41 0.99 
1 267 (38.0) 43 (38.1) 469 (34.2)    
2 265 (37.8) 50 (44.3) 548 (40.1)    
≥3 165 (23.5) 19 (16.8) 342 (25.0)    
  
 
 
    
Metastatic 
sites 
Liver only 168 (23.9) 24 (21.2) 290 (21.2) 0.47 0.85 0.94 
Liver + others 356 (50.7) 56 (49.6) 738 (54.0)    
No Liver 178 (25.4) 33 (29.2) 340 (24.9)    
  
 
 
    
Treatment 
details 
Continuous OxFp 0 (0.0) 0 (0.0) 671 (49.1) N/A N/A N/A 
Continuous 
OxFp+C 
702 (100.0) 0 (0.0) 0 (0.0)    
Intermittent OxFp 0 (0.0) 0 (0.0) 697 (50.9)    
Intermittent OxFp C 0 (0.0) 58 (51.3) 0 (0.0)    
Int. OxFp+maint C 0 (0.0) 55 (48.7) 0 (0.0)    
  
 
 
    
Fluoropyrimidi
ne partner 
Xelox 462 (65.8) 0 (0.0) 887 (64.8) 0.663 N/A 0.88 
OxMdG 240 (34.2) 113 (100.0) 481 (35.2)    
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KRAS result Wild-type 319 (55.1) 60 (61.2) 671 (59.5) 0.17 0.083 0.35 Mutated 260 (44.9) 38 (38.8) 456 (40.5)    
  
 
 
    
NRAS result Wild-type 551 (95.2) 53 (93.0) 1087 (97.1) N/A N/A N/A Mutated 28 (4.8) 4 (7.0)4 33 (2.9)    
  
 
 
    
BRAF result Wild-type 545 (93.8) 44 (80.0) 1006 (89.7) N/A N/A N/A Mutated 36 (6.2) 11 (20.0)4 116 (10.3)    
 
1Comparing patients treated with cetuximab to those without. 2Not significant after correction 
for multiple testing. 3Excluding COIN-B (i.e. comparing COIN cetuximab vs non-cetuximab). 
4In COIN-B, only carried out on KRAS wild-type CRCs. N/A – not applicable. RSJ – 
Rectosigmoid junction. Percentages in parentheses, unless otherwise stated. 
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Supplementary Table S2 - Coding region and promoter variants and their associated 
genes analysed in this study 
 
rs no. Gene Variant MAF 
rs3740199 ADAM12 Gly48Arg 0.45 
rs459552 APC Val1822Asp 0.22 
rs11938093 BTC Leu124Met 0.26 
rs9344 CCND1 Pro241 0.43 
rs2230804 CHUK Val268Ile 0.47 
rs34471628 DUSP1 Tyr187His 0.04 
rs770087 DUSP6 Ser144Ala 0.20 
rs4444903 EGF promoter 
c.1-382 A>G 0.40 
rs11568943 EGF Arg431Lys 0.06 
rs2237051 EGF Ile708Met 0.38 
rs11569017 EGF Asp784Val 0.05 
rs4698803 EGF Glu920Val 0.21 
rs2227983 EGFR Arg521Lys 0.26 
rs11568315 EGFR intron 1 (CA)n repeat 0.45 
rs17567 EPS15 Ile822Met 0.23 
rs41292521 EPS15 Ser438Leu 0.02 
rs1058808 ERBB2 Pro1170Ala 0.31 
rs78803121 EREG Cys141Phe 0.06 
rs1801274 FCGR2A His166Arg 0.48 
rs396991 FCGR3A Phe212Val 0.34 
rs4073 IL8 promoter 
c.1-352 T>A 0.46 
rs16858808 IL8RA Arg335Cys 0.03 
rs1870377 KDR Gln472His 0.23 
rs2305948 KDR Val297Ile 0.11 
rs702689 MAP3K1 Asp806Asn 0.28 
rs832582 MAP3K1 Val906Ile 0.17 
rs243865 MMP2 promoter  
c.1-2206 C>T 0.25 
rs679620 MMP3 Lys45Glu 0.48 
rs35068180 MMP3 promoter 
c.1-1671insA 0.48 
rs17576 MMP9 Gln279Arg 0.35 
rs2274756 MMP9 Arg668Gln 0.14 
rs2250889 MMP9 Arg574Pro 0.04 
rs41427445 MMP9 Asn38Ser 0.01 
rs3729680 PIK3CA Ile391Met 0.07 
rs3730089 PIK3R1 Met326Ile 0.16 
rs1011320 PIK3R2 Ser313Pro 0.05 
rs785467 PIK3R3 Asn283Lys 0.30 
rs2302524 PLAUR Lys220Arg 0.16 
rs4760 PLAUR Leu317Pro 0.16 
rs2228246 PLCG1 Ser279Gly 0.16 
rs753381 PLCG1 Ile813Thr 0.46 
rs17537869 PLCG2 Arg268Trp 0.07 
rs13283456 PTGES2 Arg298His 0.20 
rs1236913 PTGS1 Trp8Arg 0.7 
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rs5789 PTGS1 Leu237Met 0.03 
rs20417 PTGS2 promoter  
c.1-899 C>G 0.16 
rs5275 PTGS2 3’UTR  
c.1812+430 A>G 0.35 
rs751019 PTK2B Lys838Thr 0.45 
rs1284879 RASAL1 His321Arg 0.22 
rs2229712 RPS6KA1 Lys344Thr 0.22 
rs61755579 SOS2 Ala208Thr 0.03 
rs1073123 TSC1 Met322Thr 0.13 
rs602990 VAV2 Met584Val 0.47 
rs61751477 VAV2 Ile779Met 0.01 
 
MAF – Minor allele frequencies in patients from COIN and COIN-B.
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Supplementary Table S3 - Analyses of 12-week response and skin rash (SR) (primary 
endpoints) 
 
 
 Response SR 
rs no. Χ2 (df) P-value Χ2 (df) P-value 
rs9344 0.18 (2) 0.91 1.35 (2) 0.51 
rs1801274 2.41 (2) 0.30 0.08 (2) 0.96 
rs396991 1.97 (2) 0.37 0.94 (2) 0.63 
rs20417 0.87 (2) 0.65 2.72 (2) 0.26 
rs5275 6.95 (2) 0.031 5.24 (2) 0.073 
rs2227983 2.73 (2) 0.26 2.62 (2) 0.27 
rs11568315 0.40 (2) 0.82 1.37 (2) 0.50 
rs4444903 7.54 (2) 0.023 1.36 (2) 0.51 
rs11568943 1.43 (2) 0.23 1.86 (2) 0.39 
rs2237051 5.73 (2) 0.057 1.93 (2) 0.38 
rs11569017 2.96 (2) 0.086 1.12 (1) 0.29 
rs4698803 4.87 (2) 0.088 2.83 (2) 0.24 
rs11938093 2.26 (2) 0.32 0.48 (2) 0.79 
rs3729680 0.51 (2) 0.77 3.87 (2) 0.14 
rs78803121 7.44 (2) 0.024 4.59 (2) 0.10 
rs1011320 9.42 (1) 0.0021 3.59 (1) 0.058 
rs17537869 8.13 (2) 0.017 1.85 (2) 0.40 
rs2228246 1.99 (2) 0.37 2.27 (2) 0.32 
rs2302524 1.06 (2) 0.59 1.37 (2) 0.50 
rs4760 0.66 (2) 0.72 0.37 (2) 0.83 
rs679620 1.76 (2) 0.41 0.10 (2) 0.95 
rs751019 3.83 (2) 0.15 2.82 (2) 0.24 
rs753381 3.16 (2) 0.21 1.15 (2) 0.56 
rs13283456 0.99 (2) 0.61 0.56 (2) 0.76 
rs1870377 5.02 (2) 0.081 0.66 (2) 0.72 
rs2230804 0.13 (2) 0.94 1.50 (2) 0.47 
rs2305948 0.52 (2) 0.77 0.91 (2) 0.63 
rs4073 0.00 (2) 0.99 0.28 (2) 0.87 
rs602990 1.27 (2) 0.53 6.85 (2) 0.033 
rs702689 0.14 (2) 0.93 0.42 (2) 0.81 
rs785467 0.37 (2) 0.83 9.55 (2) 0.0085 
rs832582 0.92 (2) 0.63 0.77 (2) 0.68 
rs1073123 1.56 (2) 0.46 2.89 (2) 0.24 
rs1236913 0.32 (1) 0.57 0.22 (1) 0.64 
rs1284879 0.09 (2) 0.96 0.72 (2) 0.70 
rs17576 0.28 (2) 0.87 0.26 (2) 0.88 
rs2274756 0.31 (2) 0.86 1.86 (2) 0.40 
rs243865 2.74 (2) 0.25 2.54 (2) 0.28 
rs3740199 3.48 (2) 0.18 3.33 (2) 0.19 
rs459552 5.88 (2) 0.053 1.43 (2) 0.49 
rs770087 1.07 (2) 0.59 4.28 (2) 0.12 
rs1058808 2.28 (2) 0.32 3.30 (2) 0.19 
rs2229712 0.64 (2) 0.73 1.73 (2) 0.42 
rs16858808 0.60 (1) 0.44 5.29 (1) 0.022 
rs17567 3.41 (2) 0.18 0.76 (2) 0.68 
rs2250889 2.80 (1) 0.095 0.19 (1) 0.66 
rs34471628 1.11 (1) 0.29 1.54 (1) 0.21 
rs41427445 0.36 (1) 0.55 0.56 (1) 0.45 
rs5789 0.12 (1) 0.73 1.23 (1) 0.27 
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rs41292521 1.00 (1) 0.32 5.17 (1) 0.023 
rs61755579 0.07 (1) 0.79 0.13 (1) 0.72 
rs61751477 0.63 (1) 0.43 0.20 (1) 0.65 
rs3730089 0.32 (2) 0.85 1.93 (2) 0.38 
rs35068180 2.01 (2) 0.37 0.10 (2) 0.95 
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Supplementary Table S4 - Association of Ser313Pro in PIK3R2 with response to cetuximab 
 
 
 All patients 
 
KRAS mutant  KRAS wild type1 
Cetuximab + -  + -  + - 
≥1 allele encoding 
proline 
25/62 
(40.3%) 
58/117 
(49.6%) 
 
12/30 
(40.0%) 
17/40 
(42.5%) 
 
8/22 
(36.4%) 
31/55 
(56.4%) 
homozygous for 
alleles encoding 
serine 
371/614 
(60.4%) 
602/1050 
(57.3%) 
 
110/218 
(50.5%) 
191/353 
(54.1%) 
 
210/295 
(71.2%) 
317/521 
(60.8%) 
OR (95% CI) 
P-value 
0.44 (0.26, 0.75) 
0.002 
0.73 (0.50, 1.07) 
0.11 
 
0.65 (0.30, 1.43) 
0.29 
0.63 (0.32, 1.22) 
0.17 
 
0.23 (0.09, 0.56) 
0.001 
0.82 (0.47, 1.45) 
0.51 
    
 
 
Predictive for 
cetuximab? 
NO 
P interaction=0.13 
 
NO 
P interaction=0.94 
 
YES 
P interaction=0.017 
 
Numbers represent patients with that genotype that responded to treatment over all patients for whom we had data on response, with percentages in parentheses. 1On 
a RAS (KRAS and NRAS) wild-type background, 38.1% (8/21) of patients treated with cetuximab and with ≥1 allele encoding proline responded as compared to 74.0% 
(202/273) of patients homozygous for alleles encoding serine (OR 0.21, 95% CI 0.08-0.52, P=0.001 unadjusted; OR 0.22, 95% CI 0.09-0.58, P=0.002 adjusted for 
BRAF status). This was significantly predictive for cetuximab, Pinteraction=0.027 unadjusted and 0.026 adjusted (ORno cetuximab 0.73, 95% CI 0.40-1.32, P=0.30 unadjusted, 
OR 0.80, 95% CI 0.44-1.46, P=0.46 adjusted). No associations were significant after correction for multiple testing.
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Supplementary Table S5 - Association of Arg268Trp in PLCG2 with response to cetuximab 
 
 
 All patients 
 
KRAS mutant  KRAS wild type 
cetuximab + -  + -  + - 
≥1 allele encoding 
tryptophan 
62/90 
(69.9%) 
72/154 
(46.7%) 
 
22/34 
(64.7%) 
24/52 
(46.2%) 
 
32/41 
(78.1%) 
38/73 
(52.1%) 
homozygous for 
alleles encoding 
arginine 
336/589 
(57.1%) 
589/1015 
(58.0%) 
 
101/215 
(47.0%) 
184/341 
(54.0%) 
 
187/277 
(67.5%) 
311/504 
(61.7%) 
OR (95% CI) 
P-value 
1.66 (1.03, 2.67) 
0.037 
0.64 (0.45, 0.89) 
0.009 
 
2.05 (0.96, 4.40) 
0.064 
0.73 (0.41, 1.31) 
0.29 
 
1.70 (0.78, 3.73) 
0.18 
0.68 (0.41, 1.11) 
0.12 
    
 
 
Predictive for 
cetuximab? 
YES 
P interaction=0.001 
 
YES 
P interaction=0.034 
 
NO 
P interaction=0.052 
 
Numbers represent patients with that genotype that responded to treatment over all patients for whom we had data on response, with 
percentages in parentheses. 
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Supplementary Table S6 - Analyses of overall survival (OS) and overall response rate (ORR) 
(secondary endpoints) 
 
 OS ORR 
rs no. Χ2 (df) P-value Χ2 (df) P-value 
rs9344 0.72 (2) 0.70 0.74 (2) 0.69 
rs1801274 1.27 (2) 0.53 1.57 (2) 0.46 
rs396991 0.63 (2) 0.73 1.91 (2) 0.39 
rs20417 0.69 (2) 0.71 1.58 (2) 0.45 
rs5275 1.26 (2) 0.53 5.04 (2) 0.080 
rs2227983 1.00 (2) 0.61 3.48 (2) 0.18 
rs11568315 0.41 (2) 0.81 0.35 (2) 0.84 
rs4444903 3.33 (2) 0.19 5.08 (2) 0.079 
rs11568943 2.73 (2) 0.26 0.46 (1) 0.50 
rs2237051 1.87 (2) 0.39 4.34 (2) 0.11 
rs11569017 3.91 (2) 0.048 3.03 (1) 0.082 
rs4698803 1.46 (2) 0.48 1.42 (2) 0.49 
rs11938093 4.68 (2) 0.096 0.68 (2) 0.71 
rs3729680 0.75 (2) 0.69 0.85 (2) 0.65 
rs78803121 0.77 (2) 0.68 6.71 (2) 0.035 
rs1011320 7.34 (1) 0.0067 10.3 (1) 0.0014 
rs17537869 2.09 (2) 0.35 5.11 (2) 0.078 
rs2228246 2.23 (2) 0.33 2.31 (2) 0.31 
rs2302524 3.02 (2) 0.22 1.41 (2) 0.49 
rs4760 2.14 (2) 0.34 1.41 (2) 0.49 
rs679620 0.82 (2) 0.66 1.06 (2) 0.59 
rs751019 0.31 (2) 0.85 5.41 (2) 0.067 
rs753381 2.03 (2) 0.36 2.49 (2) 0.29 
rs13283456 1.42 (2) 0.49 2.98 (2) 0.23 
rs1870377 1.25 (2) 0.54 1.77 (2) 0.41 
rs2230804 0.34 (2) 0.84 0.46 (2) 0.79 
rs2305948 0.41 (2) 0.82 0.39 (2) 0.82 
rs4073 5.25 (2) 0.072 1.34 (2) 0.51 
rs602990 1.21 (2) 0.55 0.98 (2) 0.61 
rs702689 1.64 (2) 0.44 0.43 (2) 0.80 
rs785467 0.83 (2) 0.66 0.31 (2) 0.85 
rs832582 1.51 (2) 0.47 0.25 (2) 0.88 
rs1073123 2.26 (2) 0.32 1.40 (2) 0.50 
rs1236913 1.41 (1) 0.24 0.52 (1) 0.47 
rs1284879 2.78 (2) 0.25 0.98 (2) 0.61 
rs17576 2.32 (2) 0.31 0.39 (2) 0.82 
rs2274756 0.88 (2) 0.64 0.32 (2) 0.85 
rs243865 0.95 (2) 0.62 2.86 (2) 0.24 
rs3740199 0.30 (2) 0.86 3.50 (2) 0.17 
rs459552 0.17 (2) 0.92 5.24 (2) 0.073 
rs770087 1.32 (2) 0.52 1.45 (2) 0.49 
rs1058808 1.07 (2) 0.59 1.81 (2) 0.41 
rs2229712 5.86 (2) 0.054 3.46 (2) 0.18 
rs16858808 0.47 (1) 0.49 0.15 (1) 0.70 
rs17567 2.45 (2) 0.29 0.13 (2) 0.94 
rs2250889 1.96 (1) 0.16 2.90 (1) 0.089 
rs34471628 0.42 (1) 0.52 1.48 (1) 0.22 
rs41427445 0.30 (1) 0.58 1.62 (1) 0.20 
rs5789 0.24 (1) 0.62 0.40 (1) 0.53 
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rs41292521 0.32 (1) 0.57 0.84 (1) 0.36 
rs61755579 0.34 (1) 0.56 0.01 (1) 0.94 
rs61751477 3.53 (2) 0.17 0.95 (1) 0.33 
rs3730089 0.50 (2) 0.78 0.29 (2) 0.86 
rs35068180 0.23 (2) 0.89 1.06 (2) 0.59 
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Supplementary Table S7 – Analyses of individual toxicities (secondary endpoints) 
 
 
Lethargy Nausea/vomiting Diarrhoea Stomatitis HFS Hypomagnesaemia Nail changes 
rs no. Χ2 (df) P-
value χ2 (df) 
P-
value χ2 (df) 
P-
value Χ2 (df) 
P-
value χ2 (df) 
P-
value χ2 (df) P-value χ2 (df) P-value 
rs9344 1.36 (2) 0.51 4.83 (2) 0.089 0.29 (2) 0.87 0.12 (2) 0.94 1.01 (2) 0.60 0.32 (2) 0.85 0.21 (1) 0.64 
rs1801274 2.13 (2) 0.34 2.52 (2) 0.28 5.40 (2) 0.067 2.84 (2) 0.24 4.84 (2) 0.089 2.24 (2) 0.33 4.62 (2) 0.099 
rs396991 0.32 (2) 0.85 2.42 (2) 0.30 3.14 (2) 0.21 7.18 (2) 0.028 1.16 (2) 0.56 0.52 (2) 0.77 0.40 (1) 0.53 
rs20417 0.20 (2) 0.91 1.01 (2) 0.60 2.36 (2) 0.31 0.35 (2) 0.84 0.10 (2) 0.95 0.91 (1) 0.34 0.31 (1) 0.58 
rs5275 3.48 (2) 0.18 2.73 (2) 0.26 1.87 (2) 0.39 1.57 (2) 0.46 0.30 (2) 0.86 0.37 (1) 0.54 2.97 (2) 0.23 
rs2227983 1.01 (2) 0.60 3.26 (2) 0.20 0.05 (2) 0.98 0.99 (2) 0.61 3.86 (2) 0.15 0.48 (1) 0.49 2.93 (1) 0.087 
rs11568315 0.27 (2) 0.87 1.67 (2) 0.43 0.03 (2) 0.98 2.55 (2) 0.28 0.05 (2) 0.98 0.02 (1) 0.88 0.75 (2) 0.69 
rs4444903 0.98 (2) 0.61 1.37 (2) 0.51 2.03 (2) 0.36 1.75 (2) 0.42 9.42 (2) 0.0090 0.86 (2) 0.65 0.65 (2) 0.72 
rs11568943 0.01 (2) 0.99 0.82 (2) 0.66 0.18 (1) 0.67 0.79 (2) 0.67 0.23 (1) 0.63 0.06 (1) 0.81 0.11 (1) 0.74 
rs2237051 1.05 (2) 0.59 2.14 (2) 0.34 3.76 (2) 0.15 3.23 (2) 0.20 3.94 (2) 0.14 1.14 (2) 0.56 1.10 (2) 0.58 
rs11569017 0.01 (1) 0.94 0.08 (1) 0.78 0.56 (1) 0.45 1.45 (1) 0.23 0.11 (1) 0.74 0.21 (1) 0.64 0.00 (1) 0.97 
rs4698803 1.03 (2) 0.60 1.01 (2) 0.60 1.44 (2) 0.49 2.65 (2) 0.27 2.81 (2) 0.25 0.18 (1) 0.67 10.6 (2) 0.0049 
rs11938093 1.08 (2) 0.58 1.21 (2) 0.55 2.25 (2) 0.32 0.72 (2) 0.70 0.79 (2) 0.67 0.53 (2) 0.77 0.91 (2) 0.64 
rs3729680 0.39 (2) 0.82 0.57 (1) 0.45 0.27 (1) 0.61 1.52 (1) 0.22 0.48 (2) 0.79 0.00 (1) 0.99 Cannot be fitted 
rs78803121 0.41 (2) 0.82 0.79 (2) 0.67 0.95 (2) 0.62 0.06 (2) 0.97 4.08 (1) 0.043 0.10 (1) 0.76 Cannot be fitted 
rs1011320 0.46 (1) 0.50 0.00 (1) 0.98 0.25 (1) 0.62 0.73 (1) 0.39 0.25 (1) 0.62 Cannot be fitted 0.68 (1) 0.41 
rs17537869 1.69 (2) 0.43 2.39 (1) 0.12 4.09 (2) 0.13 0.14 (2) 0.93 2.29 (2) 0.32 1.02 (1) 0.31 0.27 (1) 0.60 
rs2228246 0.84 (2) 0.66 0.55 (2) 0.76 2.19 (2) 0.34 0.79 (2) 0.67 1.10 (2) 0.58 Cannot be fitted 1.90 (1) 0.17 
rs2302524 1.54 (2) 0.46 3.19 (2) 0.20 2.01 (2) 0.37 3.04 (2) 0.23 2.13 (2) 0.35 2.02 (1) 0.16 6.50 (2) 0.039 
rs4760 1.84 (2) 0.40 1.37 (2) 0.50 0.30 (2) 0.86 1.06 (2) 0.59 0.97 (2) 0.62 0.47 (1) 0.49 1.60 (2) 0.45 
rs679620 1.33 (2) 0.51 0.43 (2) 0.81 0.05 (2) 0.97 0.16 (2) 0.92 0.57 (2) 0.75 1.36 (2) 0.51 2.59 (2) 0.27 
rs751019 2.23 (2) 0.33 0.62 (2) 0.73 0.38 (2) 0.83 0.42 (2) 0.81 3.79 (2) 0.15 2.00 (2) 0.37 2.89 (2) 0.24 
rs753381 0.46 (2) 0.80 1.87 (2) 0.39 0.50 (2) 0.78 0.58 (2) 0.75 4.87 (2) 0.088 4.13 (2) 0.13 4.63 (2) 0.099 
rs13283456 0.90 (2) 0.64 2.45 (2) 0.29 2.01 (2) 0.37 8.05 (2) 0.018 4.83 (2) 0.089 0.52 (1) 0.47 0.28 (1) 0.60 
rs1870377 5.61 (2) 0.061 1.18 (2) 0.56 0.10 (2) 0.95 0.59 (2) 0.74 1.34 (2) 0.51 0.32 (1) 0.57 0.48 (1) 0.49 
rs2230804 3.50 (2) 0.17 2.04 (2) 0.36 0.70 (2) 0.70 0.50 (2) 0.78 1.31 (2) 0.52 0.74 (2) 0.69 2.03 (1) 0.15 
rs2305948 0.10 (2) 0.95 1.79 (2) 0.41 1.30 (2) 0.52 3.45 (2) 0.18 0.08 (1) 0.78 0.10 (1) 0.75 0.93 (1) 0.36 
rs4073 2.20 (2) 0.33 0.92 (2) 0.63 1.50 (2) 0.47 0.43 (2) 0.81 0.88 (2) 0.64 0.29 (2) 0.86 3.20 (2) 0.20 
rs602990 2.86 (2) 0.24 0.18 (2) 0.91 1.71 (2) 0.43 2.45 (2) 0.29 0.11 (2) 0.95 2.00 (2) 0.37 2.91 (2) 0.23 
rs702689 3.76 (2) 0.15 1.37 (2) 0.50 5.58 (2) 0.061 1.59 (2) 0.45 6.08 (2) 0.048 0.33 (1) 0.57 0.01 (1) 0.93 
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rs785467 3.79 (2) 0.15 1.03 (2) 0.60 0.41 (2) 0.81 2.37 (2) 0.31 3.10 (2) 0.21 0.15 (2) 0.93 1.02 (1) 0.31 
rs832582 8.72 (2) 0.013 2.21 (2) 0.33 6.98 (2) 0.030 0.96 (2) 0.62 2.43 (2) 0.30 2.43 (1) 0.12 0.28 (1) 0.60 
rs1073123 0.11 (2) 0.95 0.26 (2) 0.88 0.70 (2) 0.70 7.41 (2) 0.025 0.41 (2) 0.82 Cannot be fitted 0.05 (1) 0.82 
rs1236913 0.19 (1) 0.67 1.36 (1) 0.24 0.39 (1) 0.53 0.59 (1) 0.44 0.73 (1) 0.39 0.00 (1) 0.98 1.43 (1) 0.23 
rs1284879 4.72 (2) 0.094 7.71 (2) 0.021 3.73 (2) 0.16 2.61 (2) 0.27 3.08 (2) 0.21 0.90 (2) 0.64 0.53 (1) 0.47 
rs17576 5.60 (2) 0.061 5.70 (2) 0.058 2.15 (2) 0.34 5.26 (2) 0.072 4.19 (2) 0.12 1.75 (2) 0.42 2.26 (2) 0.32 
rs2274756 2.15 (2) 0.34 0.09 (1) 0.77 3.52 (2) 0.17 0.10 (1) 0.75 2.92 (2) 0.23 2.73 (1) 0.098 2.20 (1) 0.14 
rs243865 0.03 (2) 0.99 0.60 (2) 0.74 1.77 (2) 0.41 1.54 (2) 0.46 0.24 (2) 0.89 0.95 (2) 0.62 0.00 (1) 0.97 
rs3740199 4.76 (2) 0.093 0.78 (2) 0.68 0.08 (2) 0.96 0.54 (2) 0.76 3.37 (2) 0.19 0.51 (2) 0.77 0.16 (2) 0.92 
rs459552 2.64 (2) 0.27 3.37 (2) 0.19 4.68 (2) 0.096 1.86 (2) 0.39 5.34 (2) 0.069 2.09 (2) 0.35 0.51 (1) 0.48 
rs770087 0.25 (2) 0.88 0.26 (2) 0.88 1.90 (2) 0.39 0.38 (2) 0.83 0.90 (2) 0.64 1.16 (1) 0.28 0.42 (2) 0.81 
rs1058808 5.90 (2) 0.053 1.61 (2) 0.45 0.33 (2) 0.85 0.77 (2) 0.68 8.77 (2) 0.013 0.18 (2) 0.91 0.02 (2) 0.99 
rs2229712 1.09 (2) 0.58 0.91 (2) 0.63 8.05 (2) 0.018 0.65 (2) 0.72 1.11 (2) 0.58 0.21 (1) 0.65 0.18 (2) 0.91 
rs16858808 0.55 (1) 0.46 0.00 (1) 0.95 0.30 (1) 0.59 0.39 (1) 0.53 0.97 (1) 0.32 Cannot be fitted 12.6 (1) 0.00039 
rs17567 1.89 (2) 0.39 2.58 (2) 0.28 2.57 (2) 0.28 5.69 (2) 0.058 4.64 (2) 0.098 0.06 (1) 0.80 2.33 (2) 0.31 
rs2250889 0.05 (1) 0.82 4.62 (1) 0.032 0.01 (1) 0.92 0.19 (1) 0.66 2.44 (1) 0.12 0.24 (1) 0.62 1.11 (1) 0.29 
rs34471628 0.98 (1) 0.32 1.63 (1) 0.20 0.04 (1) 0.83 0.54 (1) 0.46 0.00 (1) 0.99 6.62 (1) 0.010 0.03 (1) 0.86 
rs41427445 3.16 (1) 0.075 0.04 (1) 0.84 1.05 (1) 0.30 0.15 (1) 0.70 0.10 (1) 0.76 Cannot be fitted Cannot be fitted 
rs5789 0.39 (1) 0.53 1.94 (1) 0.16 0.13 (1) 0.72 0.90 (1) 0.34 2.36 (1) 0.12 Cannot be fitted Cannot be fitted 
rs41292521 1.86 (1) 0.17 2.00 (1) 0.16 1.92 (1) 0.17 0.03 (1) 0.86 0.01 (1) 0.91 Cannot be fitted 0.35 (1) 0.56 
rs61755579 0.00 (1) 0.99 1.89 (1) 0.17 0.00 (1) 0.98 0.03 (1) 0.86 1.66 (1) 0.20 1.09 (1) 0.30 Cannot be fitted 
rs61751477 1.47 (1) 0.23 0.12 (1) 0.73 0.18 (1) 0.67 0.14 (1) 0.71 0.22 (1) 0.64 Cannot be fitted Cannot be fitted 
rs3730089 1.61 (2) 0.45 0.69 (2) 0.71 3.52 (2) 0.17 0.52 (2) 0.77 1.09 (2) 0.58 1.66 (2) 0.44 0.23 (1) 0.63 
rs35068180 0.32 (2) 0.85 2.37 (2) 0.31 3.14 (2) 0.21 7.18 (2) 0.028 1.16 (2) 0.56 0.52 (2) 0.77 0.40 (1) 0.53 
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